Covered recipient · General Payments record
NICHOLAS OSWALD IANNOTTI
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
General Payments · PY2018–2024
$5,554.94
- Reported across 232 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $486.76 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Tempus AI, Inc | $232.63 | 9 |
| Lilly USA, LLC | $103.40 | 1 |
| ABBVIE INC. | $69.30 | 3 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $35.33 | 1 |
| Janssen Biotech, Inc. | $23.50 | 1 |
| Kite Pharma, Inc. | $22.60 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $30.18 | 03/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103962979 | CMS |
| ABBVIE INC. | $18.93 | 05/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103962981 | CMS |
| ABBVIE INC. | $20.19 | 11/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103962983 | CMS |
| Janssen Biotech, Inc. | $23.50 | 11/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078512128 | CMS |
| Kite Pharma, Inc. | $22.60 | 09/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1128611743 | CMS |
| Lilly USA, LLC | $103.40 | 03/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135253312 | CMS |
| Novartis Pharmaceuticals Corporation | $35.33 | 10/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086871779 | CMS |
| Tempus AI, Inc | $24.39 | 04/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150166584 | CMS |
| Tempus AI, Inc | $87.62 | 05/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150166586 | CMS |
| Tempus AI, Inc | $26.80 | 05/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150166588 | CMS |
| Tempus AI, Inc | $6.80 | 08/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150166590 | CMS |
| Tempus AI, Inc | $5.96 | 09/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150166592 | CMS |
| Tempus AI, Inc | $17.89 | 09/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150166594 | CMS |
| Tempus AI, Inc | $28.66 | 10/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150166596 | CMS |
| Tempus AI, Inc | $9.76 | 10/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150166598 | CMS |
| Tempus AI, Inc | $24.75 | 12/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150166600 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.